A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Latest Information Update: 27 Dec 2023
At a glance
- Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms DISCOVER
- Sponsors Gilead Sciences
- 24 May 2023 This trial has been completed in Netherlands, according to the European Clinical Trials Database record.
- 24 May 2023 This trial has been completed in Netherlands, according to the European Clinical Trials Database record.
- 02 Aug 2022 Results assessing fasting concentrations of total cholesterol (TC), LDL, HDL, and triglycerides in participants who were not on PrEP at randomization, presented at the 24th International AIDS Conference.